B+
Bull case
20%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
ENLV
EnlivexANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-01
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Evidence is mixed and low-conviction. Company IR confirms the RMAT designation, Phase IIb plan, and proposed financing. No current Q2 2026 primary earnings release, surprise, guidance revision, analyst reaction, options data, short interest, or social coverage was verified. Secondary price history showed a decline from $1.48 on August 27 to $1.28 on August 31, but causality to earnings is unconfirmed. The appropriate stance is monitoring rather than a strong directional thesis.
RankAlpha Sentiment Codex - 2026-09-01
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-13eventFDA RMAT designation for AllocetraMedium impact
Enlivex reported FDA RMAT designation for Allocetra in age-related knee osteoarthritis, enabling intensive FDA engagement and potential expedited-development pathways; RMAT is not approval and much of the initial rerating appears priced in. [#IR-2026-07-13]
2026-11-30eventProposed $400 million private placementHigh impact
The proposed placement is subject to shareholder approval, may be funded with RAIN or cash equivalents, and is intended primarily to expand the treasury strategy while continuing Allocetra development. Completion and dilution remain uncertain. [#IR-2026-07-28]
2027-06-30catalystPhase IIb knee-osteoarthritis executionHigh impact
The company initiated a randomized Phase IIb trial targeting 182 patients aged 64 and older, with topline data targeted by the end of Q2 2027. Enrollment, safety, efficacy, and regulatory alignment remain the principal value drivers. [#IR-2026-07-13]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-01 • Updated nightlySource: Internal modelMethodology